Statins, or HMG-CoA reductase inhibitors, are widely used to treat hypercholesterolemia. They inhibit cholesterol synthesis, reduce LDL cholesterol levels, and lower triglycerides. Statins are well tolerated and have a good safety profile. Clinical trials show they reduce the risk of major coronary events by about 30%, especially in high-risk patients. Mechanisms include improving lipoprotein profiles, endothelial function, plaque stability, and reducing inflammation. Some benefits may be independent of LDL lowering, suggesting statins may have broader applications beyond lipid-lowering. Statins work by competitively inhibiting HMG-CoA reductase, leading to increased LDL receptor expression and reduced LDL levels. They also decrease apolipoprotein B-100 and triglyceride-rich lipoprotein synthesis. Statins are metabolized through different pathways, with variations in their pharmacokinetics affecting their use. They effectively lower LDL and modestly raise HDL, but do not affect lipoprotein(a) or LDL size and density. Common adverse effects include liver and muscle toxicity, with myopathy being a major concern. Statins can interact with other drugs, increasing the risk of myopathy. Monitoring liver enzymes and creatine kinase is important. Statins are generally safe when used in combination with other lipid-lowering agents, but caution is needed due to potential interactions. Clinical trials, such as the Scandinavian Simvastatin Survival Study (4S) and the Cholesterol And Recurrent Events (CARE) study, have shown that statins reduce coronary events and stroke risk. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study extended these findings. Primary prevention studies, like the West of Scotland Coronary Prevention Study (WOSCOPS), also demonstrated benefits in reducing coronary events. Statins have benefits beyond LDL lowering, including improving endothelial function, reducing inflammation, and affecting thrombosis. They may also reduce atherosclerosis progression and improve outcomes in patients with cerebrovascular and peripheral vascular disease. However, the relationship between LDL lowering and clinical benefits is complex, with some studies showing that significant LDL reduction may not always translate to clinical benefits. Statins are recommended for patients with atherosclerosis, diabetes, and multiple risk factors. They are particularly effective in high-risk populations. For patients with low HDL, statins may offer additional benefits. Future research will explore their role in acute coronary syndromes and stroke prevention. Despite their benefits, statins are underutilized in coronary disease patients, highlighting the need for better risk assessment and management strategies. Statins are increasingly recognized as valuable tools in the prevention and management of coronary heart disease.Statins, or HMG-CoA reductase inhibitors, are widely used to treat hypercholesterolemia. They inhibit cholesterol synthesis, reduce LDL cholesterol levels, and lower triglycerides. Statins are well tolerated and have a good safety profile. Clinical trials show they reduce the risk of major coronary events by about 30%, especially in high-risk patients. Mechanisms include improving lipoprotein profiles, endothelial function, plaque stability, and reducing inflammation. Some benefits may be independent of LDL lowering, suggesting statins may have broader applications beyond lipid-lowering. Statins work by competitively inhibiting HMG-CoA reductase, leading to increased LDL receptor expression and reduced LDL levels. They also decrease apolipoprotein B-100 and triglyceride-rich lipoprotein synthesis. Statins are metabolized through different pathways, with variations in their pharmacokinetics affecting their use. They effectively lower LDL and modestly raise HDL, but do not affect lipoprotein(a) or LDL size and density. Common adverse effects include liver and muscle toxicity, with myopathy being a major concern. Statins can interact with other drugs, increasing the risk of myopathy. Monitoring liver enzymes and creatine kinase is important. Statins are generally safe when used in combination with other lipid-lowering agents, but caution is needed due to potential interactions. Clinical trials, such as the Scandinavian Simvastatin Survival Study (4S) and the Cholesterol And Recurrent Events (CARE) study, have shown that statins reduce coronary events and stroke risk. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study extended these findings. Primary prevention studies, like the West of Scotland Coronary Prevention Study (WOSCOPS), also demonstrated benefits in reducing coronary events. Statins have benefits beyond LDL lowering, including improving endothelial function, reducing inflammation, and affecting thrombosis. They may also reduce atherosclerosis progression and improve outcomes in patients with cerebrovascular and peripheral vascular disease. However, the relationship between LDL lowering and clinical benefits is complex, with some studies showing that significant LDL reduction may not always translate to clinical benefits. Statins are recommended for patients with atherosclerosis, diabetes, and multiple risk factors. They are particularly effective in high-risk populations. For patients with low HDL, statins may offer additional benefits. Future research will explore their role in acute coronary syndromes and stroke prevention. Despite their benefits, statins are underutilized in coronary disease patients, highlighting the need for better risk assessment and management strategies. Statins are increasingly recognized as valuable tools in the prevention and management of coronary heart disease.